Silencing of lncRNA CHRM3-AS2 Expression Exerts Anti-Tumour Effects Against Glioma
CHRM3-AS2
KLF4
differentially expressed RNAs
glioma
miR-370-5p
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
01
2022
accepted:
21
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Long non-coding RNAs (lncRNAs) are key regulators involved in the progression of glioma, and many functional lncRNAs are yet to be identified. This study aimed to explore the function of CHRM3-AS2, a rarely reported lncRNA, in glioma, as well as the underlying mechanisms involving miR-370-5p/KLF4. Differentially expressed RNAs (DERs) were screened from two gene expression profiles of glioblastoma (GBM). Fluorescence CHRM3-AS2 was screened as a prognosis-associated DER in GBM. CHRM3-AS2 expression was up-regulated in glioma cells, and CHRM3-AS2 was localised in the cytoplasm. Silencing of CHRM3-AS2 expression inhibited cell viability, colony formation, migration, and invasion and promoted apoptosis of U251 and SHG-44 cells. In addition, CHRM3-AS2 targeted miR-370-5p/KLF4 in glioma cells. The anti-tumour effect of CHRM3-AS2 silencing was weakened by miR-370-5p silencing or KLF4 overexpression. Silencing of CHRM3-AS2 expression inhibited the malignant progression of glioma by regulating miR-370-5p/KLF4 expression.
Identifiants
pubmed: 35359381
doi: 10.3389/fonc.2022.856381
pmc: PMC8962832
doi:
Types de publication
Journal Article
Langues
eng
Pagination
856381Informations de copyright
Copyright © 2022 Wang, Chen, Liu, Liao and Jiang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncotarget. 2016 Dec 6;7(49):81757-81767
pubmed: 27835585
Oncotarget. 2016 Aug 23;7(34):55343-55351
pubmed: 27419373
Tumour Biol. 2017 Jun;39(6):1010428317710824
pubmed: 28631573
Oncogene. 2020 Nov;39(45):6879-6892
pubmed: 32978519
Oncol Rep. 2018 Apr;39(4):1939-1947
pubmed: 29484417
Hum Gene Ther Clin Dev. 2018 Sep;29(3):156-166
pubmed: 30180756
Nucleic Acids Res. 2017 Jan 4;45(D1):D619-D625
pubmed: 27799471
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
J Neurooncol. 2019 Jul;143(3):525-536
pubmed: 31172354
J Cell Mol Med. 2020 Jul;24(14):7767-7777
pubmed: 32424934
Int J Biol Markers. 2019 Sep;34(3):232-242
pubmed: 30968749
Neurotherapeutics. 2018 Oct;15(4):1139-1157
pubmed: 30120709
Neoplasma. 2020 Jan;67(1):111-118
pubmed: 31777264
Nat Rev Neurol. 2016 Feb;12(2):69-70
pubmed: 26782337
Life Sci. 2020 Aug 1;254:116900
pubmed: 31786194
Neurosurg Rev. 2017 Jan;40(1):1-14
pubmed: 27085859
J Recept Signal Transduct Res. 2021 Oct;41(5):442-450
pubmed: 32972267
Nucleic Acids Res. 2000 Aug 1;28(15):2969-76
pubmed: 10908361
Cancer Sci. 2021 Feb;112(2):604-618
pubmed: 33090636
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Cell Mol Med. 2018 Dec;22(12):5768-5775
pubmed: 30188595
Ther Adv Med Oncol. 2020 Aug 11;12:1758835920940936
pubmed: 32849915
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2343-2350
pubmed: 29762838
Biomed Res Int. 2021 Apr 30;2021:6680036
pubmed: 33997040
Biochem Cell Biol. 2020 Aug;98(4):466-473
pubmed: 32567955
Mediators Inflamm. 2020 May 21;2020:9752372
pubmed: 32565733
Genomics. 2020 Jan;112(1):1021-1029
pubmed: 31226483
Cell Death Dis. 2021 Oct 22;12(11):985
pubmed: 34686662
J Biochem. 2020 Apr 1;167(4):411-418
pubmed: 31899508
Mol Cancer. 2018 Feb 19;17(1):61
pubmed: 29458374
Cancer Lett. 2020 Apr 28;476:1-12
pubmed: 32044356
Clin Chim Acta. 2020 Jan;500:10-19
pubmed: 31604064
Cancer Manag Res. 2019 Dec 27;11:10807-10819
pubmed: 31920390
Biosci Rep. 2021 Jul 30;41(7):
pubmed: 33393590
Biomed Res Int. 2019 Mar 26;2019:4015969
pubmed: 31032345
Biom J. 2010 Feb;52(1):70-84
pubmed: 19937997
Biomed Res Int. 2019 Dec 7;2019:2506843
pubmed: 31886185
J Cell Mol Med. 2021 Jan;25(1):463-472
pubmed: 33336871
Cell Death Dis. 2021 Mar 24;12(4):312
pubmed: 33762574
Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):6131-6137
pubmed: 34661273
Cancer Lett. 2018 Apr 10;419:203-209
pubmed: 29355660